Results of a phase II trial with cystemustine in advanced malignant melanoma. A trial of the EORTC Clinical Screening Group
- 作者V. Urosevic; Ph. Chollet; A. Adenis; J. Chauvergne; P. Fargeot; H. Roche; P. Kerbrat; M.A. Lentz; P. Fumoleau; B. Chevallier
- 卷第32卷
- 期第1期
- 印刷ISSN0959-8049
- 文件大小278.73KB
- 发表时间1996
- DOI10.1016/0959-8049(95)00473-4
Dose-intensification of vincristine, ifosfamide, carboplatin and etoposide (V-ICE) ±rhGM-CSF in small cell lung cancerLung Cancer · 1994
Moderate dose intensification of carboplatin and etoposide as first line combination chemotherapy in small cell lung cancerEllis, P.A.; Smith, I.E.; Ashley, S.E.; Priest, K.; Talbot, D.C.; Jones, A.L.; Brada, M.; Ford, H.T. · 1993
High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administrationBenedetti Panici, P; Pierelli, L; Scambia, G; Foddai, ML; Salerno, MG; Menichella, G; Vittori, M; Maneschi, F; Caracussi, U; Serafini, R · 1997
High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk ewing sarcoma family tumors : The Bambino Gesù Children's Hospital experienceGiuseppe Maria Milano; Raffaele Cozza; Ilaria Ilari; Luigi De Sio; Renata Boldrini; Alessandro Jenkner; Maretta De Ioris; Alessandro Inserra; Carlo Dominici; Alberto Donfrancesco · 2006
Erratum: Milano GM, Cozza R, Ilari I, et al. High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk ewing sarcoma family tumors: The Bambino Gesù Children's Hospital experience. Cancer. 2006;106(8):1838–45.2006